Anuh Pharma Limited — PPTs, 28-05-2026: Investor Presentation

**Business Performance:**

Anuh Pharma's FY26 revenue reached Rs 776 Cr (+15.66% YoY), driven by strong volumes and regulated market entry. FY26 EBITDA rose 6.52% to Rs 67.84 Cr, maintaining healthy profitability. Exports made up ~46% of revenue, with Asia and Africa as key markets.

**Growth Drivers or Strategy:**

The company focuses on process innovation, cost optimization, and export-led market diversification. Strategic investments in compliance, efficiency, and capacity boost long-term growth in high-value regulatory markets.

**Recent Developments:**

Anuh Pharma successfully cleared USFDA and EU GMP inspections. They achieved record production volumes with high plant utilization and boosted capacity to 2400 MTPA in 2025. R&D targets high-value niche APIs.

**Key Financial Metrics:**

FY26 Net Profit (PAT) was Rs 41.05 Cr (-13.32% YoY), with EPS at Rs 4.10.

**Management Commentary / Outlook:**

Management anticipates 15-20% annual growth, confident in sustained value through regulated market opportunities and a diversified portfolio. New anti-ulcerative and anti-TB products are under development.